Validation of the Chinese EORTC chronic lymphocytic leukaemia module – application of classical test theory and item response theory

[1] Buzaglo J(2017)Chronic lymphocytic leukemia patient reported outcomes and quality of life: findings from the cancer experience registry Blood 130 2122-20

[2] Miller M(2018)Is there an epidemic of chronic lymphocytic leukaemia (CLL) in China? Leuk Res 73 16-3391

[3] Zaleta A(2018)Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience Blood. 131 1910-2906

[4] Johnson J(2009)First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia Blood 114 3382-S182

[5] Mcmanus S(2015)Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study Qual Life Res 24 2895-2832

[6] Karten C(2019)Prolonged improvement in patient reported quality of life (QoL) following Tisagenlecleucel infusion in adult patients (pts) with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL): 19-month follow-up (FU) of the Juliet study Biol Blood Marrow Transplant 25 S181-1287

[7] Yang S(2017)Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus Leuk Lymphoma 58 2824-345

[8] Gale RP(2019)Regulatory type 1 T cell infusion in mismatched related or unrelated hematopoietic stem cell transplantation (HSCT) for hematologic malignancies Biol Blood Marrow Transplant 25 S182-307

[9] Shi H(2019)Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment Am J Hematol 94 1266-1675

[10] Liu Y(2018)International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia Qual Life Res 27 333-30

[1] Buzaglo J(2017)Chronic lymphocytic leukemia patient reported outcomes and quality of life: findings from the cancer experience registry Blood 130 2122-20

[2] Miller M(2018)Is there an epidemic of chronic lymphocytic leukaemia (CLL) in China? Leuk Res 73 16-3391

[3] Zaleta A(2018)Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience Blood. 131 1910-2906

[4] Johnson J(2009)First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia Blood 114 3382-S182

[5] Mcmanus S(2015)Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study Qual Life Res 24 2895-2832

[6] Karten C(2019)Prolonged improvement in patient reported quality of life (QoL) following Tisagenlecleucel infusion in adult patients (pts) with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL): 19-month follow-up (FU) of the Juliet study Biol Blood Marrow Transplant 25 S181-1287

[7] Yang S(2017)Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus Leuk Lymphoma 58 2824-345

[8] Gale RP(2019)Regulatory type 1 T cell infusion in mismatched related or unrelated hematopoietic stem cell transplantation (HSCT) for hematologic malignancies Biol Blood Marrow Transplant 25 S182-307

[9] Shi H(2019)Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment Am J Hematol 94 1266-1675

[10] Liu Y(2018)International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia Qual Life Res 27 333-30